Boston, MA 08/06/2013 (wallstreetpr) – During the last trading session, the shares of Inovio Pharmaceuticals Inc (NYSEMKT:INO) have increased by 6.73% to the price of $ 2.22. A total number of 2.89 million shares were traded during the last trading session. It was announced by Inovio Pharmaceuticals Inc that the utilization of the company’s proprietary technology of electroporation has led to the significant enhancements in the abilities of the DNA therapy. This DNA therapy has enhanced properties for stimulating the growth of blood vessels and this growth might be beneficial in the treatment for critical limb ischemia as well as few other forms of the diseases of peripheral arteries. The results proving these aspects were published in a research paper in Journal of Vascular Surgery which is one of the peer-reviewed journals.
More of good news is coming from Inovio Pharmaceuticals Inc which is a relatively smaller biotech company. During the last month, the company seemed to have rallied by 115%. It was reported by Inovio Pharmaceuticals Inc that the company’s H7N9 DNA vaccine component was observed to protect 100%, every vaccinated animal that was inoculated with the vaccine in the clinical trials. Followed by this positive result, Inovio Pharmaceuticals Inc has reported that the company’s next generation HIV vaccine, Pennvax-B when combined with CELLECTRA, the effectiveness of the vaccine was enhanced in a phase 1 clinical trial. Despite these positive and enhanced results produced by the pipeline candidates of Inovio Pharmaceuticals Inc, one need to be more cautious before making an investment in of Inovio Pharmaceuticals Inc. This is because for the reason that the company is holding a history of generating not anything more than loss for the period of over 30 years. During last week, it was announced by the company that the preclinical studies with the hTERT DNA vaccine for cancer directed with the help of CELLECTRA have produced immune responses.
